title: Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies.
abstract: OBJECTIVE
  To compare hematopoietic recovery, duration of hospitalization, and 100-day survival in patients who received allogeneic-blood stem cells (BSC) or conventional allogeneic bone marrow transplantation (BMT).
  
  
  METHODS
  From December 1994 to August 1995, 21 patients participated in a phase II study of allogeneic BSC transplantation. Cells mobilized with granulocyte colony-stimulating factor (G-CSF; 5 micrograms/kg/ d) were collected from human leukocyte antigen (HLA)-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. G-CSF (10 micrograms/kg/d) was administered posttransplant. The outcomes were compared with 22 identically treated historical patients who received allogeneic BMT.
  
  
  RESULTS
  The median infused CD34+ cell and granulocyte-macrophage colony-forming unit (CFU-GM) content were 7.73 x 10(4)/kg and 41.6 x 10(4)/kg, respectively. The median time to a neutrophil count greater than 500/ microL was 11 days after BSC and 16.5 days after BMT (P = .0003). A trend toward faster platelet and RBC recovery after BSC was observed. BSC patients received fewer platelet transfusions: 10 versus 19 (P = .015). The median length of hospitalization was shorter after BSC transplantation: 25 versus 31.5 days (P = .0243). The 100-day survival rates were similar: 83% after BSC and 75% after BMT (P = .3585). The incidence of acute GVHD grade II to IV was 57% and 45% for BSC and BMT, respectively (P = .4654).
  
  
  CONCLUSIONS
  In comparison to BMT, allogeneic BSC transplantation may result in faster hematopoietic recovery, shorter hospital stay, and similar early survival. Whether allogeneic BSC are superior to bone marrow needs to be determined in randomized trials.
authors.affiliation: Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3330, USA.
authors.forename: Z S
authors.initials: ZS
authors.lastname: Pavletic
authors.forename: M R
authors.initials: MR
authors.lastname: Bishop
authors.forename: S R
authors.initials: SR
authors.lastname: Tarantolo
authors.forename: S
authors.initials: S
authors.lastname: Martin-Algarra
authors.forename: P J
authors.initials: PJ
authors.lastname: Bierman
authors.forename: J M
authors.initials: JM
authors.lastname: Vose
authors.forename: E C
authors.initials: EC
authors.lastname: Reed
authors.forename: T G
authors.initials: TG
authors.lastname: Gross
authors.forename: J
authors.initials: J
authors.lastname: Kollath
authors.forename: K
authors.initials: K
authors.lastname: Nasrati
authors.forename: J D
authors.initials: JD
authors.lastname: Jackson
authors.forename: J O
authors.initials: JO
authors.lastname: Armitage
authors.forename: A
authors.initials: A
authors.lastname: Kessinger
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor; D019337:Hematologic Neoplasms / Q000503:physiopathology* / Q000601:surgery*; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D014019:Tissue Donors; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor